News Category
Onco-Innovations has entered into a letter of intent to acquire an exclusive option on Ifowonco's oral small-molecule LAG-3 inhibitor program, potenti...
Creative Biolabs has expanded its complement assay services, offering advanced tools like C3b deposition and hemolytic inhibition assays to support pr...
Quantum BioPharma's Lucid-MS targets myelin preservation rather than immune suppression, offering a potential new approach to treating multiple sclero...
Silo Pharma's receipt of a Canadian patent allowance for its lead asset SPC-15 strengthens its intellectual property position and advances its PTSD tr...
Quantum BioPharma's FDA-cleared phase 2 trial of Lucid-MS highlights a shift in MS treatment toward myelin protection, addressing the unmet need of pr...
Regentis Biomaterials received a Japanese Notice of Allowance for its GelrinC manufacturing process, expanding its global IP portfolio to nearly 30 pa...
VERAXA Biotech's collaboration with Ardigen aims to use AI to enhance its oncology pipeline, potentially reviving abandoned drug targets and improving...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize its oncology pipeline, potentially reducing development risks and reviving abandoned t...
The American Heart Association's 2026 Health Tech Competition aims to bridge the gap between promising health technologies and patient care, seeking m...
Scientists have identified a protein on glioblastoma cells that could be targeted to make the cancer more vulnerable to existing treatments, potential...
NanoViricides is set to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessible trea...
Helus Pharma's appointments of Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board signal strategic preparation ...
The 20th Annual Sickle Cell Disease Educational Summit, hosted by Cayenne Wellness Center, underscores two decades of progress in treatment and advoca...
Helix BioPharma's appointment of a seasoned oncology executive signals a strategic shift towards advancing its lead candidate L-DOS47 and preparing LE...
Quantum BioPharma's significant cost reductions and FDA approval for its Phase 2 trial of Lucid-MS signal a strategic push to develop a treatment for ...
Regentis Biomaterials is progressing its GelrinC cartilage repair implant through a pivotal U.S. trial while simultaneously scaling manufacturing and ...
Alpha Cognition's second-quarter results show accelerating demand for ZUNVEYL, with revenue up 71% sequentially and a path to profitability, despite s...
Two lung cancer research organizations fund two promising young scientists to tackle early detection and drug resistance, addressing critical gaps in ...
PX1 Research's domestically manufactured research peptides now pass a seven-stage testing protocol at 99%+ purity, setting a new benchmark for quality...
A comprehensive review in World Journal of Pediatric Surgery synthesizes operative strategies for necrotizing enterocolitis, emphasizing bowel preserv...
Onco-Innovations is progressing its precision oncology pipeline by advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor, through critical manu...
Regentis Biomaterials' GelrinC, a cell-free hydrogel implant, gains European approval for a more efficient manufacturing process, enhancing scalabilit...
Researchers at the University of Manchester discovered that a subset of immune cells, often overlooked, is vital for initiating and sustaining the imm...
Quantum BioPharma reports significant expense reductions and FDA approval for its Phase 2 trial of Lucid-MS in progressive multiple sclerosis, strengt...
Regentis Biomaterials is accelerating GelrinC's path to market by simultaneously advancing US pivotal trials and European commercialization, potential...
Lantern Pharma's Q2 2026 results highlight progress in its AI-driven oncology pipeline and the establishment of Open Medicine AI as a separate company...
Helus Pharma reports progress in its Phase 3 program for depression treatment HLP003, with topline data expected in Q4 2026, highlighting significant ...
DM Clinical Research marks its 20th anniversary, highlighting its growth into a leading network of over 35 research sites and its impact on accelerati...
NeOnc Technologies' lead candidate NEO100 met its primary endpoint in a Phase 2a trial for recurrent brain cancer, with median overall survival of 26....
PX1 Research expands its dual-incretin peptide catalog with domestically manufactured Retatrutide and Tirzepatide peptides, each batch verified via HP...
Quantum BioPharma's focus on progression independent of relapse activity (PIRA) and chronic active lesions in MS development signals a shift toward ad...
GeoVax offers its MVA-based hemorrhagic fever vaccine candidates and expertise to support the response to the escalating Ebola outbreak in Congo, whil...
Drugmakers worldwide are investing nearly $500 billion in U.S. facilities to mitigate planned import tariffs, with implications for drug pricing and s...
Nutriband's CEO will present at the 2026 Georgia Life Sciences Summit, underscoring the company's innovative AVERSA technology aimed at preventing opi...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant step toward a potential neuroprotective therapy for mult...
PX1 Research introduces US-manufactured sublingual peptide strips for needle-free research, offering verified purity and cGMP compliance.
PX1 Research's adoption of seven-stage HPLC purity testing and cGMP standards in US-based manufacturing ensures batch-specific documentation, addressi...
NanoViricides has received approval to start a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessibl...
Research from the University of Virginia suggests focused ultrasound can enhance drug delivery to gliomas, potentially improving brain cancer treatmen...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in triple-negative breast cancer models, s...
Quantum BioPharma's FDA clearance for Lucid-MS to enter Phase 2 trials marks a pivotal step in developing a neuroprotective therapy for multiple scler...
Tonix Pharmaceuticals' second-quarter 2026 revenue surged to $13.5 million, primarily due to impressive TONMYA sales, signaling robust market adoption...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA sales, demonstrating commercial viability and supporting pipeline pro...
Tonix Pharmaceuticals' second-quarter revenue jumped to $13.5 million driven by TONMYA's strong launch, positioning the company for sustained growth i...
A new narrative review provides a comprehensive framework for risk-adapted neuroblastoma care, emphasizing molecular and clinical factors to tailor tr...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration implant through clinical trials, FDA submission preparation, and European comm...
Quantum BioPharma advances a two-pronged approach to neurological health, combining its investigational MS therapy Lucid-MS with its supplement unbuzz...
Quantum BioPharma is advancing a two-pronged approach to neurological health, targeting myelin repair in multiple sclerosis with Lucid-MS and addressi...
